← Back to headlines
Mesoblast Reports Strong Revenue Growth Amid Commercial Transition
Biotech company Mesoblast has reported a significant increase in annual revenue, reaching approximately $115 million to $120 million as it shifts toward commercial operations. The financial results highlight growing market adoption of its therapeutic products.
27 Aug, 00:32 — 27 Aug, 00:32
Sources
Showing 1 of 2 sources
Coverage Timeline
First report: investing-com · 26 Aug, 23:45|Full coverage: 2 · 47m|Window: 47m
Left-leaningCenterRight-leaning
